ACAD10抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07741(ACAD10 Antibody) at dilution 1/10. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07741(ACAD10 Antibody) at dilution 1/10. (Original magnification: ×200)    

  
  

The ACAD10 antibody targets acyl-CoA dehydrogenase family member 10 (ACAD10), a mitochondrial enzyme belonging to the acyl-CoA dehydrogenase family, which plays a role in fatty acid β-oxidation. ACAD10 is implicated in cellular energy metabolism, though its precise substrate specificity and biological functions remain less characterized compared to other ACAD family members (e.g., ACADM or ACADVL). Recent studies suggest ACAD10 may regulate metabolic pathways beyond fatty acid oxidation, including interactions with mTOR signaling. For instance, ACAD10 upregulation has been linked to mTOR inhibition, influencing cell growth, autophagy, and stress responses.

Research highlights ACAD10's potential involvement in metabolic disorders, cancer, and longevity. In humans, ACAD10 variants are associated with type 2 diabetes and obesity, while its overexpression in certain cancers (e.g., lung adenocarcinoma) correlates with poor prognosis. ACAD10 antibodies are essential tools for detecting protein expression, localization, and quantification in tissues or cell lines, aiding investigations into its metabolic and disease-related roles. Commercial ACAD10 antibodies are typically validated for applications like Western blotting, immunohistochemistry, or immunofluorescence. However, specificity challenges may arise due to structural similarities within the ACAD family, necessitating careful validation. Ongoing research aims to clarify ACAD10's molecular mechanisms and therapeutic potential in metabolic and neoplastic diseases.